Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
AZD0156 is an inhibitor of ataxia telangiectasia mutated (ATM) kinase, which leads to defective DNA damage repair and apoptosis in tumor cells (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD0156||ATM Inhibitor 6||AZD0156 is an inhibitor of ataxia telangiectasia mutated (ATM) kinase, which leads to defective DNA damage repair and apoptosis in tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KMT2A - MLLT1 NRAS G12D||acute myeloid leukemia||predicted - sensitive||AZD0156||Preclinical||Actionable||In a preclinical study, AZD0156 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).||27625305|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02588105||Phase I||Olaparib AZD0156||Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer||Active, not recruiting|